ライフサイエンスコーパス: FK-506

1 -loading capacity are additive with those of FK 506.

2 blocked by co-infusion of the CaN inhibitor, FK-506.

3 w cells followed by antilymphocyte serum and FK-506.

4 vitamin E, MnTBAP, L-N-acetyl-cysteine, and FK-506.

5 rapamycin reversed the inhibitory actions of FK-506.

6 s with aortic banding, LVH was unaffected by FK 506 (0.3 mg.kg-1.d-1) or even higher doses of CsA (10

7 tojanin I, is inhibited by cyclosporin A and FK-506 (0.5 microM), two drugs that specifically block t

8 Mice received tacrolimus (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 6

9 FK-506 (2 microM), a specific blocker of PP2B, reduced t

10 ne during hyperglycemia declined less in the FK-506 (28%) and CsA groups (29%) compared with controls

11 Yet the calcineurin inhibitor FK-506 (500 nM) did not prolong the openings of human ch

12 smmPBj14 were treated with one of two drugs: FK-506, a potent immunosuppressive agent, or PMPA, a pot

13 the combined effect of AMD3100 and low-dose FK-506 (AF) can reduce the adhesion score significantly

14 ere treated with cyclosporine and seven with FK-506 along with prednisone and azathioprine post-PTX.

15 FK-506 also accelerated the rest decay of SR Ca2+ conten

16 FK-506 also inhibited potentiation of cAMP levels when c

17 FK-506 also inhibits Na(+)-Ca2+ exchange, although this

18 , and 9 were immunosuppressed with 0.5 mg/kg FK 506, although the remaining groups with 1 mg/kg FK 50

19 alcineurin antagonists cyclosporin A and the FK-506 analogue, ascomycin, diminished costimulatory mol

20 statistically lower in patients treated with FK-506 and CsA (5.05+/-0.47 and 5.05+/-0.42 mg/kg/min) a

21 e after arginine stimulation observed in the FK-506 and CsA groups as compared with controls (754%+/-

22 differences on low maintenance doses between FK-506 and CsA.

23 e effects of low dose maintenance therapy of FK-506 and Cyclosporin A (CsA) in 14 patients 1 year aft

24 FK-506 and cyclosporin inhibited augmentation of cAMP le

25 apy (anti-alphabeta-TCR monoclonal antibody, FK-506, and anti-lymphocyte serum).

26 mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated

27 PCB 95 and FK 506 are used to examine the relationship between ryan

28 DA-approved drugs, we identified tacrolimus (FK-506) as the most potent activator of ALK1 signaling i

29 d glucocorticoid-inducible kinase (SGK1) and FK 506 binding protein 5, genes known to be important in

30 FKBP6 has a putative N-terminal FK-506 binding and peptidylproyl isomerase (rotamase) do

31 FKBP6 shows homology to the FK-506 binding protein (FKBP) class of immunophilins.

32 FK-506 binding protein (FKBP) has been reported to be cl

33 The immunophilin, FKBP20-2, belongs to the FK-506 binding protein (FKBP) subfamily that functions a

34 With HF, expression of RyR2 and FK-506 binding protein 12.6 (FKBP12.6) were reduced, whe

35 can microarray techniques, the intracellular FK-506 binding protein 4 (FKBP4) was identified to bind

36 rivative induced rapid dimerization of FKBP (FK-506 binding protein) and FRB (FKBP-rapamycin binding

37 t of potent nonimmunosuppressive ligands for FK-506 binding proteins (FKBPs).

38 onventional PPIases, cyclophilins and FKBPs (FK-506 binding proteins).

39 D (SlyD) and Thermococcus gammatolerans SlyD FK-506-binding protein (FKBP) domains suitable for prese

40 s a previously uncharacterized member of the FK-506-binding protein (FKBP) gene family down-regulated

41 ppressive ligand of the immunophilin FKBP12 (FK-506-binding protein 12 kDa), has previously been show

42 complexes partially involving the inhibitor FK-506-binding protein 12.

43 ng protein-like 1 (AIPL1) is a member of the FK-506-binding protein family expressed specifically in

44 s, the calcium-binding protein S100P and the FK-506-binding protein FKBP51, was decreased following a

45 The rough endoplasmic reticulum-resident FK-506-binding protein FKBP65 can be isolated from chick

46 y-6-nitro-7-sulfonyl-benzo[f]quinoxaline) or FK-506 blocked the hypoxic seizure-induced increase in C

47 llular cAMP levels; the inhibitory effect of FK-506 but not of cyclosporin A was attenuated by rapamy

48 tion of apoptosis was markedly suppressed by FK-506 calcineurin inhibitor.

49 FK-506 can inhibit the activity of FKBP, thereby reversi

50 at the commonly used immunosuppressive agent FK-506 can inhibit TRPC6 activity in vivo.

51 In most cells, FK-506 caused an increase in SR Ca2+ content during stea

52 immunosuppression or in the presence of MMF/FK-506 combination.

53 Preincubation of cells with 0.1 microM FK-506 completely prevented carbachol-induced augmentati

54 FK-506 did not affect SR Ca2+ uptake but modestly decrea

55 c immunosuppressant drugs cyclosporine A and FK-506 displayed very low background and a remarkable dy

56 ics, and in an earlier report we showed that FK-506 enhanced the fibrogenic process in in vivo and in

57 Rapamycin, an agent that competes with FK-506 for the immunophilin, FK binding protein 12, does

58 , although the remaining groups with 1 mg/kg FK 506, from day 0 to 4 after transplant.

59 owever, at day 15 rats receiving 1 mg/day of FK 506 had a significantly lower number of apoptotic cel

60 We conclude that FK-506 increases the fraction of SR Ca2+ released during

61 Ca2+ current were unaltered, suggesting that FK-506 increases the fraction of SR Ca2+ released during

62 eas these two indicators represent increased FK-506-independent DNA turnover activities in thymocytes

63 FK-506-induced synaptic potentiation was expressed in ad

64 The immunosuppressants cyclosporin A and FK-506 inhibited the increase in APP mRNA and holoprotei

65 Intracellular addition of EGTA or FK-506 into CN-15-transfected cells induced an up to 5-f

66 yte profiles, renal function parameters, and FK 506 levels in the postoperative period up until eithe

67 magnesium losses, which correlated with high FK 506 levels.

68 electrolyte abnormalities continue, to which FK 506-mediated renal toxicity might contribute.

69 yclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) were identified and compared with

70 Short course tacrolimus (FK-506) monotherapy was withdrawn at postoperative day 2

71 mmunosuppressive agents (e.g., cyclosporine, FK-506, mycophenolate mofetil, azathioprine, OKT-3, anti

72 provide further evidence that the actions of FK-506 on cholera toxin-treated gastric chief cells are

73 on between immunophilin FKBP12 and Ry1R with FK 506 or rapamycin completely eliminates PCB 95-enhance

74 e inhibition of postsynaptic CaN activity by FK-506 or an autoinhibitory peptide induced synaptic pot

75 lls were dialyzed with either cyclosporin A, FK-506, or calcineurin autoinhibitory peptide (structura

76 PBMC proliferation was blocked in vitro with FK-506, pig-tailed macaques treated preinoculation with

77 cineurin inhibitors, cyclosporin A (CsA) and FK 506, prevent pressure-overload LVH using 2 standard r

78 Since the discovery that FK-506 promotes neurite outgrowth, considerable attentio

79 ssants mycophenolic acid, cyclosporin A, and FK-506 provide a potential explanation for a reduced inc

80 neurin inhibitors, such as cyclosporin A and FK-506, rely upon binding sites on both subunits for com

81 FK 506 selectively eliminates PCB 95-induced Ca2+ releas

82 FK-506 significantly increased steady state twitch Ca2+

83 in vivo administration of the CaN inhibitor FK-506 significantly suppressed hypoxic seizures, and po

84 he immunosuppressive drugs cyclosporin A and FK-506 suggest that it is involved in both positive and

85 and graft survival rates have improved with FK-506 (Tacrolimus) immunosuppression.

86 udy subjects received either cyclosporine or FK-506/tacrolimus as part of their immunosuppressive reg

87 the calcineurin inhibitors cyclosporin A and FK-506, to scavengers of ROS, and to inhibitors of calci

88 (P = 0.003) in the presence of anti-CD3/MMF/FK-506 treatment for liver-Tx and BM-Tx, respectively.

89 Synaptic potentiation induced by FK-506 was significantly attenuated by co-injecting BAPT

90 inhibitor and immunosuppressant tacrolimus (FK-506) was prevented by Npas4 overexpression.

91 -tailed macaques treated preinoculation with FK-506 were not protected from acutely lethal disease.

92 essed by the calcineurin-dependent inhibitor FK-506, which has no effect on these activities in thymo

93 the peptide inhibition is not reversed with FK-506, which indicates a distinct mechanism.